AUSTIN, Texas & HYDERABAD, India--(BUSINESS WIRE)--Biotechnology companies Heparinex, L.L.C. and Choncept, L.L.C. announced today option and license agreements with Biological E., Limited (BE), a leading biopharmaceutical company based out of India. The agreement provides BE with an option for novel production technologies for both heparin- and chondroitin-related carbohydrate compounds. Heparinex and Choncept are funded and managed by life sciences venture firm Emergent Technologies, Inc., and both companies are headed by Chief Scientist Dr. Paul DeAngelis.
